Clinical Trials
9 trialsNCT05083481 2026-05-05
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Active not recruiting
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04492033 2025-01-27
A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Handok Inc.
Phase 1/2 Terminated
NCT06139211 2024-12-20
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT05824455 2024-09-05
A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
Phase 1/2 Terminated
NCT05865925 2024-04-25
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors
Luye Pharma Group Ltd.
Phase 1/2 Unknown
NCT05177276 2022-01-04
Selinexor Combination Ph 1 Study
Hackensack Meridian Health
Phase 1/2 Withdrawn
NCT00990912 2010-02-05
A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)
Bristol-Myers Squibb
Phase 1/2 Completed
NCT00004923 2009-08-25
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
Yale University
Phase 1/2 Completed